nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—PDGFRA—penis—type 1 diabetes mellitus	0.0198	0.0746	CbGeAlD
Regorafenib—RET—autonomic nervous system—type 1 diabetes mellitus	0.0196	0.0738	CbGeAlD
Regorafenib—Infarction—Ramipril—type 1 diabetes mellitus	0.0147	0.155	CcSEcCtD
Regorafenib—DDR2—retina—type 1 diabetes mellitus	0.00848	0.0319	CbGeAlD
Regorafenib—DDR2—cardiovascular system—type 1 diabetes mellitus	0.00717	0.027	CbGeAlD
Regorafenib—FRK—lymphoid tissue—type 1 diabetes mellitus	0.00672	0.0253	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—type 1 diabetes mellitus	0.00603	0.0227	CbGeAlD
Regorafenib—EPHX2—retina—type 1 diabetes mellitus	0.00573	0.0216	CbGeAlD
Regorafenib—EPHX2—nephron tubule—type 1 diabetes mellitus	0.00539	0.0203	CbGeAlD
Regorafenib—Myocardial ischaemia—Ramipril—type 1 diabetes mellitus	0.00507	0.0534	CcSEcCtD
Regorafenib—EPHA2—islet of Langerhans—type 1 diabetes mellitus	0.00498	0.0188	CbGeAlD
Regorafenib—Endocrine disorder—Ramipril—type 1 diabetes mellitus	0.00492	0.0518	CcSEcCtD
Regorafenib—Liver injury—Ramipril—type 1 diabetes mellitus	0.00485	0.051	CcSEcCtD
Regorafenib—FLT1—islet of Langerhans—type 1 diabetes mellitus	0.0047	0.0177	CbGeAlD
Regorafenib—RAF1—islet of Langerhans—type 1 diabetes mellitus	0.00467	0.0176	CbGeAlD
Regorafenib—Proteinuria—Ramipril—type 1 diabetes mellitus	0.00464	0.0489	CcSEcCtD
Regorafenib—Protein urine present—Ramipril—type 1 diabetes mellitus	0.00458	0.0482	CcSEcCtD
Regorafenib—FLT4—cardiovascular system—type 1 diabetes mellitus	0.00437	0.0165	CbGeAlD
Regorafenib—UGT1A9—kidney—type 1 diabetes mellitus	0.00434	0.0163	CbGeAlD
Regorafenib—FLT1—retina—type 1 diabetes mellitus	0.00402	0.0151	CbGeAlD
Regorafenib—EPHA2—nephron tubule—type 1 diabetes mellitus	0.00401	0.0151	CbGeAlD
Regorafenib—FLT1—nephron tubule—type 1 diabetes mellitus	0.00378	0.0143	CbGeAlD
Regorafenib—RET—kidney—type 1 diabetes mellitus	0.00377	0.0142	CbGeAlD
Regorafenib—RAF1—nephron tubule—type 1 diabetes mellitus	0.00376	0.0142	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—type 1 diabetes mellitus	0.00367	0.0138	CbGeAlD
Regorafenib—FGFR2—cardiovascular system—type 1 diabetes mellitus	0.00367	0.0138	CbGeAlD
Regorafenib—EPHA2—cardiovascular system—type 1 diabetes mellitus	0.0036	0.0136	CbGeAlD
Regorafenib—FGFR2—kidney—type 1 diabetes mellitus	0.00359	0.0135	CbGeAlD
Regorafenib—TEK—cardiovascular system—type 1 diabetes mellitus	0.00351	0.0132	CbGeAlD
Regorafenib—EPHA2—pancreas—type 1 diabetes mellitus	0.0035	0.0132	CbGeAlD
Regorafenib—TEK—kidney—type 1 diabetes mellitus	0.00344	0.013	CbGeAlD
Regorafenib—PDGFRB—islet of Langerhans—type 1 diabetes mellitus	0.00344	0.0129	CbGeAlD
Regorafenib—TEK—pancreas—type 1 diabetes mellitus	0.00342	0.0129	CbGeAlD
Regorafenib—FLT1—cardiovascular system—type 1 diabetes mellitus	0.0034	0.0128	CbGeAlD
Regorafenib—KDR—retina—type 1 diabetes mellitus	0.0034	0.0128	CbGeAlD
Regorafenib—RAF1—cardiovascular system—type 1 diabetes mellitus	0.00338	0.0127	CbGeAlD
Regorafenib—Gastroenteritis—Ramipril—type 1 diabetes mellitus	0.00334	0.0352	CcSEcCtD
Regorafenib—FLT1—kidney—type 1 diabetes mellitus	0.00332	0.0125	CbGeAlD
Regorafenib—RAF1—kidney—type 1 diabetes mellitus	0.00331	0.0125	CbGeAlD
Regorafenib—FLT1—pancreas—type 1 diabetes mellitus	0.0033	0.0124	CbGeAlD
Regorafenib—RAF1—pancreas—type 1 diabetes mellitus	0.00328	0.0124	CbGeAlD
Regorafenib—RET—lymphoid tissue—type 1 diabetes mellitus	0.00324	0.0122	CbGeAlD
Regorafenib—KDR—nephron tubule—type 1 diabetes mellitus	0.0032	0.012	CbGeAlD
Regorafenib—PDGFRA—cardiovascular system—type 1 diabetes mellitus	0.00318	0.012	CbGeAlD
Regorafenib—ABL1—islet of Langerhans—type 1 diabetes mellitus	0.00306	0.0115	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—type 1 diabetes mellitus	0.00303	0.0114	CbGeAlD
Regorafenib—Hyponatraemia—Ramipril—type 1 diabetes mellitus	0.00297	0.0313	CcSEcCtD
Regorafenib—UGT1A1—kidney—type 1 diabetes mellitus	0.00297	0.0112	CbGeAlD
Regorafenib—TEK—lymphoid tissue—type 1 diabetes mellitus	0.00295	0.0111	CbGeAlD
Regorafenib—KDR—cardiovascular system—type 1 diabetes mellitus	0.00287	0.0108	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—type 1 diabetes mellitus	0.00286	0.0108	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—type 1 diabetes mellitus	0.00284	0.0107	CbGeAlD
Regorafenib—KIT—nephron tubule—type 1 diabetes mellitus	0.00283	0.0107	CbGeAlD
Regorafenib—KDR—kidney—type 1 diabetes mellitus	0.00281	0.0106	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—type 1 diabetes mellitus	0.00268	0.0101	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Ramipril—type 1 diabetes mellitus	0.00267	0.0281	CcSEcCtD
Regorafenib—ABL1—retina—type 1 diabetes mellitus	0.00262	0.00987	CbGeAlD
Regorafenib—KIT—cardiovascular system—type 1 diabetes mellitus	0.00255	0.00959	CbGeAlD
Regorafenib—KIT—kidney—type 1 diabetes mellitus	0.00249	0.00938	CbGeAlD
Regorafenib—PDGFRB—cardiovascular system—type 1 diabetes mellitus	0.00249	0.00937	CbGeAlD
Regorafenib—KIT—pancreas—type 1 diabetes mellitus	0.00247	0.00932	CbGeAlD
Regorafenib—ABL1—nephron tubule—type 1 diabetes mellitus	0.00247	0.00929	CbGeAlD
Regorafenib—PDGFRB—kidney—type 1 diabetes mellitus	0.00243	0.00916	CbGeAlD
Regorafenib—PDGFRB—pancreas—type 1 diabetes mellitus	0.00242	0.0091	CbGeAlD
Regorafenib—KDR—lymphoid tissue—type 1 diabetes mellitus	0.00241	0.00909	CbGeAlD
Regorafenib—Neutropenia—Ramipril—type 1 diabetes mellitus	0.00239	0.0252	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Ramipril—type 1 diabetes mellitus	0.00226	0.0238	CcSEcCtD
Regorafenib—Acute coronary syndrome—Ramipril—type 1 diabetes mellitus	0.00225	0.0237	CcSEcCtD
Regorafenib—Myocardial infarction—Ramipril—type 1 diabetes mellitus	0.00224	0.0235	CcSEcCtD
Regorafenib—Stomatitis—Ramipril—type 1 diabetes mellitus	0.00222	0.0234	CcSEcCtD
Regorafenib—ABL1—cardiovascular system—type 1 diabetes mellitus	0.00222	0.00835	CbGeAlD
Regorafenib—ABL1—kidney—type 1 diabetes mellitus	0.00217	0.00817	CbGeAlD
Regorafenib—Hepatobiliary disease—Ramipril—type 1 diabetes mellitus	0.00216	0.0227	CcSEcCtD
Regorafenib—ABL1—pancreas—type 1 diabetes mellitus	0.00215	0.00811	CbGeAlD
Regorafenib—KIT—lymphoid tissue—type 1 diabetes mellitus	0.00214	0.00806	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—type 1 diabetes mellitus	0.00209	0.00787	CbGeAlD
Regorafenib—Connective tissue disorder—Ramipril—type 1 diabetes mellitus	0.00201	0.0212	CcSEcCtD
Regorafenib—Erythema multiforme—Ramipril—type 1 diabetes mellitus	0.00194	0.0204	CcSEcCtD
Regorafenib—ABL1—lymphoid tissue—type 1 diabetes mellitus	0.00186	0.00702	CbGeAlD
Regorafenib—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.00185	0.0194	CcSEcCtD
Regorafenib—Alopecia—Ramipril—type 1 diabetes mellitus	0.00181	0.019	CcSEcCtD
Regorafenib—Malnutrition—Ramipril—type 1 diabetes mellitus	0.00178	0.0188	CcSEcCtD
Regorafenib—Tremor—Ramipril—type 1 diabetes mellitus	0.00167	0.0176	CcSEcCtD
Regorafenib—Leukopenia—Ramipril—type 1 diabetes mellitus	0.0016	0.0168	CcSEcCtD
Regorafenib—ABCG2—nephron tubule—type 1 diabetes mellitus	0.00156	0.00586	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.00151	0.0159	CcSEcCtD
Regorafenib—Dry mouth—Ramipril—type 1 diabetes mellitus	0.00148	0.0156	CcSEcCtD
Regorafenib—CYP2B6—nephron tubule—type 1 diabetes mellitus	0.00144	0.00541	CbGeAlD
Regorafenib—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.00143	0.015	CcSEcCtD
Regorafenib—Thrombocytopenia—Ramipril—type 1 diabetes mellitus	0.00142	0.015	CcSEcCtD
Regorafenib—Skin disorder—Ramipril—type 1 diabetes mellitus	0.00141	0.0149	CcSEcCtD
Regorafenib—CYP2C8—kidney—type 1 diabetes mellitus	0.00141	0.0053	CbGeAlD
Regorafenib—CYP2B6—cardiovascular system—type 1 diabetes mellitus	0.00129	0.00486	CbGeAlD
Regorafenib—CYP2C9—cardiovascular system—type 1 diabetes mellitus	0.00128	0.00481	CbGeAlD
Regorafenib—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.00126	0.0133	CcSEcCtD
Regorafenib—CYP2B6—kidney—type 1 diabetes mellitus	0.00126	0.00475	CbGeAlD
Regorafenib—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.00126	0.0132	CcSEcCtD
Regorafenib—Fatigue—Ramipril—type 1 diabetes mellitus	0.00125	0.0132	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ramipril—type 1 diabetes mellitus	0.00119	0.0125	CcSEcCtD
Regorafenib—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.00115	0.0121	CcSEcCtD
Regorafenib—Abdominal pain—Ramipril—type 1 diabetes mellitus	0.00115	0.0121	CcSEcCtD
Regorafenib—CYP2B6—lymphoid tissue—type 1 diabetes mellitus	0.00108	0.00408	CbGeAlD
Regorafenib—Asthenia—Ramipril—type 1 diabetes mellitus	0.00104	0.011	CcSEcCtD
Regorafenib—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.000996	0.0105	CcSEcCtD
Regorafenib—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.000953	0.00359	CbGeAlD
Regorafenib—CYP3A4—kidney—type 1 diabetes mellitus	0.000952	0.00359	CbGeAlD
Regorafenib—Vomiting—Ramipril—type 1 diabetes mellitus	0.000925	0.00974	CcSEcCtD
Regorafenib—Rash—Ramipril—type 1 diabetes mellitus	0.000917	0.00966	CcSEcCtD
Regorafenib—Dermatitis—Ramipril—type 1 diabetes mellitus	0.000917	0.00965	CcSEcCtD
Regorafenib—Headache—Ramipril—type 1 diabetes mellitus	0.000912	0.00959	CcSEcCtD
Regorafenib—Nausea—Ramipril—type 1 diabetes mellitus	0.000864	0.0091	CcSEcCtD
Regorafenib—ABCB1—retina—type 1 diabetes mellitus	0.000815	0.00307	CbGeAlD
Regorafenib—ABCB1—nephron tubule—type 1 diabetes mellitus	0.000767	0.00289	CbGeAlD
Regorafenib—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.000689	0.0026	CbGeAlD
Regorafenib—ABCB1—kidney—type 1 diabetes mellitus	0.000674	0.00254	CbGeAlD
Regorafenib—ABCB1—pancreas—type 1 diabetes mellitus	0.00067	0.00252	CbGeAlD
Regorafenib—ABCB1—lymphoid tissue—type 1 diabetes mellitus	0.000579	0.00218	CbGeAlD
Regorafenib—ABL1—Immune System—TYK2—type 1 diabetes mellitus	2.37e-05	3.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—EGFR—type 1 diabetes mellitus	2.37e-05	3.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF2—type 1 diabetes mellitus	2.37e-05	3.7e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—type 1 diabetes mellitus	2.35e-05	3.67e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.34e-05	3.65e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—HBA1—type 1 diabetes mellitus	2.33e-05	3.64e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOC3—type 1 diabetes mellitus	2.31e-05	3.62e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.31e-05	3.6e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—G6PC2—type 1 diabetes mellitus	2.29e-05	3.59e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—INS—type 1 diabetes mellitus	2.29e-05	3.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—type 1 diabetes mellitus	2.28e-05	3.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CD86—type 1 diabetes mellitus	2.28e-05	3.56e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.28e-05	3.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—EGFR—type 1 diabetes mellitus	2.28e-05	3.56e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—type 1 diabetes mellitus	2.28e-05	3.56e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTT1—type 1 diabetes mellitus	2.27e-05	3.55e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—INS—type 1 diabetes mellitus	2.27e-05	3.55e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—type 1 diabetes mellitus	2.27e-05	3.55e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.27e-05	3.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—type 1 diabetes mellitus	2.26e-05	3.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—type 1 diabetes mellitus	2.26e-05	3.54e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—type 1 diabetes mellitus	2.26e-05	3.53e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—type 1 diabetes mellitus	2.26e-05	3.53e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—type 1 diabetes mellitus	2.26e-05	3.53e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL2—type 1 diabetes mellitus	2.25e-05	3.53e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL2—type 1 diabetes mellitus	2.25e-05	3.52e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TYK2—type 1 diabetes mellitus	2.25e-05	3.51e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—INS—type 1 diabetes mellitus	2.24e-05	3.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.23e-05	3.49e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CD80—type 1 diabetes mellitus	2.23e-05	3.48e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—type 1 diabetes mellitus	2.22e-05	3.47e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—type 1 diabetes mellitus	2.22e-05	3.47e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.22e-05	3.47e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NOS3—type 1 diabetes mellitus	2.21e-05	3.45e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ITPR3—type 1 diabetes mellitus	2.21e-05	3.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—type 1 diabetes mellitus	2.2e-05	3.44e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.2e-05	3.43e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CD80—type 1 diabetes mellitus	2.19e-05	3.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TYK2—type 1 diabetes mellitus	2.17e-05	3.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—E2F1—type 1 diabetes mellitus	2.16e-05	3.38e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ITPR3—type 1 diabetes mellitus	2.15e-05	3.37e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—type 1 diabetes mellitus	2.15e-05	3.36e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GCG—type 1 diabetes mellitus	2.14e-05	3.34e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—INS—type 1 diabetes mellitus	2.1e-05	3.29e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.1e-05	3.28e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.1e-05	3.28e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	2.09e-05	3.27e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HBA1—type 1 diabetes mellitus	2.08e-05	3.25e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CD80—type 1 diabetes mellitus	2.08e-05	3.24e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CD80—type 1 diabetes mellitus	2.07e-05	3.24e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—INS—type 1 diabetes mellitus	2.07e-05	3.23e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOC3—type 1 diabetes mellitus	2.06e-05	3.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—type 1 diabetes mellitus	2.06e-05	3.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.05e-05	3.21e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.05e-05	3.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—type 1 diabetes mellitus	2.04e-05	3.2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—type 1 diabetes mellitus	2.04e-05	3.18e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.03e-05	3.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—type 1 diabetes mellitus	2.03e-05	3.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—type 1 diabetes mellitus	2.03e-05	3.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—type 1 diabetes mellitus	2.03e-05	3.18e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.03e-05	3.17e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—type 1 diabetes mellitus	2.03e-05	3.17e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	2.03e-05	3.17e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTT1—type 1 diabetes mellitus	2.03e-05	3.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2—type 1 diabetes mellitus	2.03e-05	3.17e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.02e-05	3.16e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EGFR—type 1 diabetes mellitus	2.01e-05	3.15e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	2.01e-05	3.15e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ITPR3—type 1 diabetes mellitus	2.01e-05	3.15e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.01e-05	3.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TYK2—type 1 diabetes mellitus	2e-05	3.13e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—type 1 diabetes mellitus	2e-05	3.13e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF1—type 1 diabetes mellitus	2e-05	3.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—type 1 diabetes mellitus	1.99e-05	3.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.99e-05	3.11e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.99e-05	3.11e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCC8—type 1 diabetes mellitus	1.99e-05	3.11e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.98e-05	3.1e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—type 1 diabetes mellitus	1.98e-05	3.1e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2—type 1 diabetes mellitus	1.98e-05	3.1e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	1.98e-05	3.09e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2—type 1 diabetes mellitus	1.98e-05	3.09e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2—type 1 diabetes mellitus	1.97e-05	3.09e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOS3—type 1 diabetes mellitus	1.97e-05	3.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—type 1 diabetes mellitus	1.96e-05	3.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—INS—type 1 diabetes mellitus	1.96e-05	3.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—INS—type 1 diabetes mellitus	1.96e-05	3.06e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—INS—type 1 diabetes mellitus	1.93e-05	3.02e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—INS—type 1 diabetes mellitus	1.93e-05	3.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—type 1 diabetes mellitus	1.9e-05	2.97e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.9e-05	2.97e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HBA1—type 1 diabetes mellitus	1.89e-05	2.96e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—type 1 diabetes mellitus	1.89e-05	2.96e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.89e-05	2.96e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOC3—type 1 diabetes mellitus	1.88e-05	2.94e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.88e-05	2.94e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—type 1 diabetes mellitus	1.88e-05	2.94e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.87e-05	2.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CD80—type 1 diabetes mellitus	1.86e-05	2.92e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EGFR—type 1 diabetes mellitus	1.85e-05	2.89e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTT1—type 1 diabetes mellitus	1.85e-05	2.89e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.85e-05	2.89e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—type 1 diabetes mellitus	1.85e-05	2.89e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.84e-05	2.88e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EGFR—type 1 diabetes mellitus	1.84e-05	2.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—type 1 diabetes mellitus	1.82e-05	2.85e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EGFR—type 1 diabetes mellitus	1.82e-05	2.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—type 1 diabetes mellitus	1.81e-05	2.83e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—type 1 diabetes mellitus	1.81e-05	2.83e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.81e-05	2.83e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GCG—type 1 diabetes mellitus	1.81e-05	2.83e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CAT—type 1 diabetes mellitus	1.81e-05	2.83e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2—type 1 diabetes mellitus	1.81e-05	2.82e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—type 1 diabetes mellitus	1.77e-05	2.77e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—type 1 diabetes mellitus	1.77e-05	2.77e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.76e-05	2.76e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—INS—type 1 diabetes mellitus	1.76e-05	2.75e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.75e-05	2.74e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—type 1 diabetes mellitus	1.75e-05	2.74e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.75e-05	2.74e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.75e-05	2.73e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—type 1 diabetes mellitus	1.75e-05	2.73e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.73e-05	2.71e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EGFR—type 1 diabetes mellitus	1.72e-05	2.7e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EGFR—type 1 diabetes mellitus	1.72e-05	2.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.72e-05	2.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.72e-05	2.68e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EGFR—type 1 diabetes mellitus	1.71e-05	2.67e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.71e-05	2.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—type 1 diabetes mellitus	1.7e-05	2.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.7e-05	2.66e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2—type 1 diabetes mellitus	1.7e-05	2.66e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.7e-05	2.66e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—NOS3—type 1 diabetes mellitus	1.69e-05	2.65e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—NOS3—type 1 diabetes mellitus	1.69e-05	2.65e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.69e-05	2.64e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2—type 1 diabetes mellitus	1.69e-05	2.64e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EGFR—type 1 diabetes mellitus	1.68e-05	2.62e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.67e-05	2.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CD80—type 1 diabetes mellitus	1.66e-05	2.6e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—type 1 diabetes mellitus	1.66e-05	2.6e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—INS—type 1 diabetes mellitus	1.64e-05	2.56e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GCG—type 1 diabetes mellitus	1.61e-05	2.53e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.6e-05	2.51e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EGFR—type 1 diabetes mellitus	1.59e-05	2.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EGFR—type 1 diabetes mellitus	1.59e-05	2.48e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	1.58e-05	2.46e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.57e-05	2.46e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—type 1 diabetes mellitus	1.57e-05	2.46e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—KCNJ11—type 1 diabetes mellitus	1.57e-05	2.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—INS—type 1 diabetes mellitus	1.57e-05	2.46e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.57e-05	2.45e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—type 1 diabetes mellitus	1.56e-05	2.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EGFR—type 1 diabetes mellitus	1.55e-05	2.42e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—type 1 diabetes mellitus	1.55e-05	2.42e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.55e-05	2.42e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.54e-05	2.41e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—type 1 diabetes mellitus	1.54e-05	2.4e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAT—type 1 diabetes mellitus	1.53e-05	2.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—type 1 diabetes mellitus	1.52e-05	2.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.52e-05	2.38e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.51e-05	2.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	1.51e-05	2.36e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EGFR—type 1 diabetes mellitus	1.51e-05	2.36e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—type 1 diabetes mellitus	1.5e-05	2.35e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GCG—type 1 diabetes mellitus	1.47e-05	2.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.46e-05	2.28e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.46e-05	2.28e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.46e-05	2.28e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—type 1 diabetes mellitus	1.45e-05	2.27e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—NOS3—type 1 diabetes mellitus	1.44e-05	2.25e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.43e-05	2.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—type 1 diabetes mellitus	1.43e-05	2.24e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—type 1 diabetes mellitus	1.42e-05	2.22e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.42e-05	2.22e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—type 1 diabetes mellitus	1.42e-05	2.21e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.4e-05	2.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—type 1 diabetes mellitus	1.4e-05	2.19e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—type 1 diabetes mellitus	1.4e-05	2.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—type 1 diabetes mellitus	1.38e-05	2.16e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.38e-05	2.15e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAT—type 1 diabetes mellitus	1.37e-05	2.14e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	1.33e-05	2.09e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ITPR3—type 1 diabetes mellitus	1.33e-05	2.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—type 1 diabetes mellitus	1.33e-05	2.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—type 1 diabetes mellitus	1.32e-05	2.07e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.32e-05	2.06e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—type 1 diabetes mellitus	1.31e-05	2.05e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.31e-05	2.05e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—type 1 diabetes mellitus	1.31e-05	2.05e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.3e-05	2.04e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.29e-05	2.02e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.29e-05	2.02e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—type 1 diabetes mellitus	1.29e-05	2.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—type 1 diabetes mellitus	1.28e-05	1.99e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HBA1—type 1 diabetes mellitus	1.25e-05	1.95e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAT—type 1 diabetes mellitus	1.25e-05	1.95e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOC3—type 1 diabetes mellitus	1.24e-05	1.94e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.23e-05	1.93e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.23e-05	1.92e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—type 1 diabetes mellitus	1.22e-05	1.91e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.22e-05	1.91e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—type 1 diabetes mellitus	1.22e-05	1.91e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—type 1 diabetes mellitus	1.22e-05	1.91e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—INS—type 1 diabetes mellitus	1.2e-05	1.88e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.2e-05	1.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—type 1 diabetes mellitus	1.19e-05	1.86e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.17e-05	1.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.17e-05	1.83e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.17e-05	1.83e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—type 1 diabetes mellitus	1.16e-05	1.82e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—type 1 diabetes mellitus	1.16e-05	1.82e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—type 1 diabetes mellitus	1.16e-05	1.81e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.11e-05	1.74e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.11e-05	1.74e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.1e-05	1.72e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—type 1 diabetes mellitus	1.1e-05	1.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—type 1 diabetes mellitus	1.1e-05	1.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—type 1 diabetes mellitus	1.06e-05	1.66e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—type 1 diabetes mellitus	1.05e-05	1.65e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—INS—type 1 diabetes mellitus	1.02e-05	1.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—type 1 diabetes mellitus	1e-05	1.57e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—type 1 diabetes mellitus	1e-05	1.57e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—type 1 diabetes mellitus	9.92e-06	1.55e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.82e-06	1.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—type 1 diabetes mellitus	9.8e-06	1.53e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCG—type 1 diabetes mellitus	9.71e-06	1.52e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—type 1 diabetes mellitus	9.32e-06	1.46e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—type 1 diabetes mellitus	9.19e-06	1.44e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—INS—type 1 diabetes mellitus	9.07e-06	1.42e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—type 1 diabetes mellitus	9.03e-06	1.41e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—type 1 diabetes mellitus	8.93e-06	1.4e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—type 1 diabetes mellitus	8.92e-06	1.39e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—INS—type 1 diabetes mellitus	8.86e-06	1.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—type 1 diabetes mellitus	8.57e-06	1.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—type 1 diabetes mellitus	8.55e-06	1.34e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—type 1 diabetes mellitus	8.32e-06	1.3e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—INS—type 1 diabetes mellitus	8.27e-06	1.29e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAT—type 1 diabetes mellitus	8.22e-06	1.29e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	8.12e-06	1.27e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—type 1 diabetes mellitus	7.96e-06	1.24e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	7.77e-06	1.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—type 1 diabetes mellitus	7.7e-06	1.2e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—type 1 diabetes mellitus	7.59e-06	1.19e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—type 1 diabetes mellitus	7.26e-06	1.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—type 1 diabetes mellitus	6.86e-06	1.07e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—INS—type 1 diabetes mellitus	5.46e-06	8.53e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—type 1 diabetes mellitus	5e-06	7.82e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—type 1 diabetes mellitus	4.79e-06	7.48e-06	CbGpPWpGaD
